Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Heliyon Année : 2021

Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha

Résumé

Cancer is one of the main causes of human mortality worldwide and novel chemotherapeutics are required due to the limitations of conventional cancer therapies. For example, using redox selenium compounds as novel chemotherapeutics seem to be very promising. The objective of this study was to explore if folate could be used as a carrier to deliver a newly synthesised selenium derivative selenofolate into cancer cells. Particularly, the cytotoxic effects of this selenofolate compound were investigated in a variety of cancer cell types including lung, liver, and cervical cancers and specifically IGROV1 cells. Our results showed that selenofolate inhibits the growth of cancer cells in-vitro. However, despite the expectations, folate receptor alpha (FRα) was not involved in the transportation of selenofolate compound into the cells i.e. growth inhibition was independent of FRα, suggesting that multiple transporters (e.g. reduced folate carrier-1) are possibly involved in the delivery and internalisation of folate in IGROV1 cells. Additionally, selenofolate did not exert cell death through apoptosis. Instead, anti-proliferative activity showed to be the main cause of growth inhibition of selenolofate in the IGROV1 cell line. In conclusion, selenofolate inhibits the growth of cancer cells and thus, may be explored further as a potential chemotherapeutic agent.
Fichier principal
Vignette du fichier
Heliyon 2021 final folate.pdf (1.26 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03372748 , version 1 (11-10-2021)

Licence

Paternité

Identifiants

Citer

Ali Razaghi, Antje Maria Zickler, Julian Spallholz, Gilbert Kirsch, Mikael Björnstedt. Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha. Heliyon, 2021, 7 (6), pp.e07254. ⟨10.1016/j.heliyon.2021.e07254⟩. ⟨hal-03372748⟩
28 Consultations
40 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More